PT3192529T - Componentes terapêuticos de ligação à superfície celular armados com amatoxina destinados à terapia de tumores - Google Patents
Componentes terapêuticos de ligação à superfície celular armados com amatoxina destinados à terapia de tumoresInfo
- Publication number
- PT3192529T PT3192529T PT171581192T PT17158119T PT3192529T PT 3192529 T PT3192529 T PT 3192529T PT 171581192 T PT171581192 T PT 171581192T PT 17158119 T PT17158119 T PT 17158119T PT 3192529 T PT3192529 T PT 3192529T
- Authority
- PT
- Portugal
- Prior art keywords
- amatoxin
- cell surface
- surface binding
- binding components
- components designed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16769009P | 2009-04-08 | 2009-04-08 | |
US22222709P | 2009-07-01 | 2009-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3192529T true PT3192529T (pt) | 2020-04-16 |
Family
ID=42269753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT171581192T PT3192529T (pt) | 2009-04-08 | 2010-04-08 | Componentes terapêuticos de ligação à superfície celular armados com amatoxina destinados à terapia de tumores |
Country Status (14)
Country | Link |
---|---|
US (2) | US9233173B2 (pt) |
EP (3) | EP3192529B1 (pt) |
AU (1) | AU2010234334B2 (pt) |
CA (3) | CA2970774C (pt) |
CY (1) | CY1122855T1 (pt) |
DK (1) | DK3192529T3 (pt) |
ES (2) | ES2784829T3 (pt) |
HR (1) | HRP20200612T1 (pt) |
HU (1) | HUE050296T2 (pt) |
LT (1) | LT3192529T (pt) |
PL (1) | PL3192529T3 (pt) |
PT (1) | PT3192529T (pt) |
SI (1) | SI3192529T1 (pt) |
WO (1) | WO2010115629A2 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110140124A (ko) * | 2009-04-08 | 2011-12-30 | 하인즈 파울스티히 | 암치료용 아미톡신-활성 표적 결합 부위 |
US10080799B2 (en) * | 2010-02-12 | 2018-09-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions related to glycoprotein-immunoglobulin fusions |
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
EP2497499A1 (en) * | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
US20150218220A1 (en) * | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
EP2774624A1 (en) * | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
JP6321687B2 (ja) * | 2014-03-10 | 2018-05-09 | ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマトキシン誘導体 |
CN103948872B (zh) * | 2014-05-12 | 2017-02-15 | 胡梁谱 | 一种治疗银屑病关节炎的中药 |
CA2957354A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EA201790545A1 (ru) | 2014-09-12 | 2017-07-31 | Дженентек, Инк. | Антитела и иммуноконъюгаты против her2 |
US9751946B2 (en) | 2014-09-12 | 2017-09-05 | Genentech, Inc. | Anti-CLL-1 antibodies and immunoconjugates |
EP3215519A1 (en) | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
PL3268047T3 (pl) | 2015-03-09 | 2024-03-18 | Heidelberg Pharma Research Gmbh | Nowe koniugaty amatoksyna-przeciwciało |
AU2016246707B2 (en) | 2015-04-06 | 2021-03-25 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
US11098131B2 (en) | 2015-07-31 | 2021-08-24 | Sutro Biopharma, Inc. | Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
AU2016360828B2 (en) | 2015-11-27 | 2021-06-24 | Heidelberg Pharma Research Gmbh | Derivatives of gamma-amanitin |
EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
MX2018012803A (es) * | 2016-04-20 | 2019-06-24 | Hangzhou Dac Biotech Co Ltd | Derivados de las toxinas de amanita y su conjugacion a una molecula de union celular. |
US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック, インコーポレイテッド | 部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法 |
US11013816B2 (en) | 2016-05-31 | 2021-05-25 | Sorrento Therapeutics, Inc. | Antibody drug conjugates having derivatives of amatoxin as the drug |
AU2017204139B2 (en) * | 2016-06-17 | 2018-08-09 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
MA45408A (fr) * | 2016-06-17 | 2019-04-24 | Magenta Therapeutics Inc | Compositions et procédés pour la déplétion des cellules cd117+ |
EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
MX2019007604A (es) | 2016-12-23 | 2019-08-16 | Heidelberg Pharma Res Gmbh | Novedoso conjugado de amanitina. |
CN106810467A (zh) * | 2017-01-03 | 2017-06-09 | 苏州昊帆生物股份有限公司 | 二胺类化合物单Boc保护方法 |
US10576161B2 (en) * | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
NZ757008A (en) * | 2017-04-06 | 2022-04-29 | Hangzhou Dac Biotech Co Ltd | Conjugation of a cytotoxic drug with bis-linkage |
BR112020001345A2 (pt) | 2017-08-07 | 2020-08-11 | Heidelberg Pharma Gmbh | método inovador para síntese de amanitinas |
WO2019030171A1 (en) | 2017-08-07 | 2019-02-14 | Heidelberg Pharma Gmbh | NOVEL METHOD FOR SYNTHESIZING AMANITINES |
EP3738608A4 (en) * | 2017-08-18 | 2021-12-08 | Sichuan Baili Pharm Co. Ltd | NON-NATURAL AMATOXIN TYPE ANTIBODY CONJUGATE |
BR112020005605A2 (pt) | 2017-09-22 | 2020-10-13 | Heidelberg Pharma Research Gmbh | novos conjugados de amanitina direcionados a psma |
AU2018355244A1 (en) | 2017-10-24 | 2020-04-09 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
CN111601616A (zh) | 2017-10-24 | 2020-08-28 | 美真达治疗公司 | 用于耗尽cd117+细胞的组合物和方法 |
WO2019102435A1 (en) | 2017-11-27 | 2019-05-31 | Euro-Celtique S.A. | Humanized antibodies targeting human tissue factor |
BR112020010662A2 (pt) * | 2017-11-29 | 2020-11-10 | Magenta Therapeutics, Inc. | composições e métodos para a depleção de células cd5+ |
MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
JP2022533430A (ja) * | 2019-05-23 | 2022-07-22 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 切断可能なリンカーを有する抗体薬物複合体 |
AR120218A1 (es) * | 2019-10-15 | 2022-02-02 | Heidelberg Pharma Res Gmbh | Conjugados de amatoxina y anticuerpo específico de linfocitos b |
EP4213886A1 (en) | 2020-09-18 | 2023-07-26 | Araris Biotech AG | Transglutaminase conjugation method with amino acid-based linkers |
PE20231512A1 (es) | 2020-10-25 | 2023-09-26 | Araris Biotech Ag | Medios y metodos para producir conjugados de ligador-anticuerpo |
EP4240424A1 (en) | 2020-11-04 | 2023-09-13 | Heidelberg Pharma Research GmbH | Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy |
JP2024512478A (ja) | 2021-03-19 | 2024-03-19 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bリンパ球特異的アマトキシン抗体コンジュゲート |
WO2023072934A1 (en) | 2021-10-25 | 2023-05-04 | Araris Biotech Ag | Methods for producing antibody-linker conjugates |
WO2023161291A1 (en) | 2022-02-22 | 2023-08-31 | Araris Biotech Ag | Peptide linkers comprising two or more payloads |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US7009034B2 (en) * | 1996-09-23 | 2006-03-07 | Incept, Llc | Biocompatible crosslinked polymers |
WO2002036142A2 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
ES2350248T3 (es) * | 2001-10-01 | 2011-01-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Procedimiento de producción de bibliotecas de proteínas y de selección de proteínas a partir de las mismas. |
US6890765B2 (en) * | 2001-11-02 | 2005-05-10 | Roche Diagnostics Operations, Inc. | Particles for immunoassays and methods for treating the same |
EP1661584A1 (en) | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
EP2015782A4 (en) * | 2006-04-12 | 2010-04-07 | Crosslink Genetics Corp | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION |
ATE521366T1 (de) | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
-
2010
- 2010-04-08 LT LTEP17158119.2T patent/LT3192529T/lt unknown
- 2010-04-08 EP EP17158119.2A patent/EP3192529B1/en active Active
- 2010-04-08 EP EP10713429.8A patent/EP2416804B1/en active Active
- 2010-04-08 PT PT171581192T patent/PT3192529T/pt unknown
- 2010-04-08 EP EP18214020.2A patent/EP3485912A1/en not_active Withdrawn
- 2010-04-08 US US13/263,287 patent/US9233173B2/en active Active
- 2010-04-08 ES ES17158119T patent/ES2784829T3/es active Active
- 2010-04-08 HU HUE17158119A patent/HUE050296T2/hu unknown
- 2010-04-08 SI SI201031993T patent/SI3192529T1/sl unknown
- 2010-04-08 DK DK17158119.2T patent/DK3192529T3/da active
- 2010-04-08 ES ES10713429.8T patent/ES2621104T3/es active Active
- 2010-04-08 PL PL17158119T patent/PL3192529T3/pl unknown
- 2010-04-08 AU AU2010234334A patent/AU2010234334B2/en active Active
- 2010-04-08 CA CA2970774A patent/CA2970774C/en active Active
- 2010-04-08 CA CA3026727A patent/CA3026727C/en active Active
- 2010-04-08 CA CA2758201A patent/CA2758201C/en active Active
- 2010-04-08 WO PCT/EP2010/002205 patent/WO2010115629A2/en active Application Filing
-
2015
- 2015-11-30 US US14/954,266 patent/US10513559B2/en active Active
-
2020
- 2020-04-07 CY CY20201100329T patent/CY1122855T1/el unknown
- 2020-04-09 HR HRP20200612TT patent/HRP20200612T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20200612T1 (hr) | 2020-08-07 |
WO2010115629A2 (en) | 2010-10-14 |
AU2010234334A1 (en) | 2011-11-10 |
DK3192529T3 (da) | 2020-04-20 |
AU2010234334B2 (en) | 2014-10-09 |
CA2758201C (en) | 2017-08-01 |
HUE050296T2 (hu) | 2020-11-30 |
ES2621104T3 (es) | 2017-07-03 |
US9233173B2 (en) | 2016-01-12 |
CA2970774C (en) | 2019-01-08 |
EP3192529B1 (en) | 2020-03-25 |
CY1122855T1 (el) | 2021-05-05 |
US20160089450A1 (en) | 2016-03-31 |
EP3192529A1 (en) | 2017-07-19 |
WO2010115629A3 (en) | 2010-12-23 |
EP3485912A1 (en) | 2019-05-22 |
PL3192529T3 (pl) | 2020-08-24 |
EP2416804B1 (en) | 2017-03-01 |
EP2416804A2 (en) | 2012-02-15 |
SI3192529T1 (sl) | 2020-07-31 |
ES2784829T3 (es) | 2020-10-01 |
CA3026727C (en) | 2022-03-22 |
US20120100161A1 (en) | 2012-04-26 |
LT3192529T (lt) | 2020-06-25 |
CA2970774A1 (en) | 2010-10-14 |
US10513559B2 (en) | 2019-12-24 |
CA3026727A1 (en) | 2010-10-14 |
CA2758201A1 (en) | 2010-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT3192529T (lt) | Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai | |
HUS1800001I1 (hu) | Kombinációs terápia COPD-hez | |
PL2440287T3 (pl) | Urządzenie do terapii fotodynamicznej | |
IL215764A0 (en) | Adjuvant cancer therapy | |
GB0916666D0 (en) | Photodynamic therapy device | |
EP2412405A4 (en) | DEVICE FOR RADIOTHERAPY | |
GB2496805B (en) | Compounds for photodynamic therapy | |
HK1172257A1 (en) | Combination therapy for treating proliferative diseases | |
HK1174571A1 (en) | Combination therapy for copd copd | |
EP2432539A4 (en) | HYPERTHERMIA ASSISTED RADIOTHERAPY | |
PL2957292T3 (pl) | Terapia w przypadku bielactwa nabytego | |
EP2440137A4 (en) | TABLE TOP FOR RADIOTHERAPY | |
EP2486929A4 (en) | ANTI-TUMOR THERAPEUTIC AGENT | |
EP2585115A4 (en) | ANTICANCER TREATMENT | |
GB0901465D0 (en) | Compounds for use in therapy | |
ZA201201894B (en) | Pharmaceutical combination for treating tumor | |
EP2473613A4 (en) | KREBSAUSHUNGERUNGSTHERAPIE | |
GB0913603D0 (en) | Cancer therapy | |
GB0921102D0 (en) | Cancer Therapy | |
GB201020513D0 (en) | Cancer therapy | |
GB0914820D0 (en) | WATerian therapy | |
GB0903319D0 (en) | Therapy | |
GB0903321D0 (en) | Therapy | |
GB0921244D0 (en) | Therapy | |
ZA201208905B (en) | Cancer therapy method |